ArticlePloS one2021
Opioid Treatment Deserts: Concept development and application in a US Midwestern urban county.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 37 citations in OpenAlex.
- Telemedicine and increased retention in medications for opioid use disorder treatment.Addiction science & clinical practice · 2026Article
- Travel Time to Methadone Treatment Via Personal Vehicle vs Public Transit.JAMA network open · 2026Article
- Medication literacy and treatment adherence in people living with human immunodeficiency virus: Mediating effects of psychosocial factors.World journal of psychiatry · 2025Review
- Emergency Medical Services-Led Outreach Following Opioid-Associated Overdose: Frequency, Modality, and Treatment Linkage.Prehospital emergency care · 2025Article
- Accessibility of Opioid Treatment Programs Based on Conventional vs Perceived Travel Time Measures.JAMA network open · 2024Article
- RREACT: A mobile multidisciplinary response to overdose.Journal of community safety & well-being · 2024Article
- Public transport access to drug treatment before and during COVID-19: Implications for the opioid epidemic.The International journal on drug policy · 2023Article
- Opioid overdose prevention education in Texas during the COVID-19 pandemic.Harm reduction journal · 2023Article
- Critical access medication for opioid use disorder (MOUD) treatment facilities in the continental United States.Drug and alcohol dependence reports · 2023Article
- Multidimensional assessment of access to medications for opioid use disorder across urban and rural communities: A scoping review.The International journal on drug policy · 2023Article
- Where Opioid Overdose Patients Live Far From Treatment: Geospatial Analysis of Underserved Populations in New York State.JMIR public health and surveillance · 2022Article
- Assessment of Community-Level Vulnerability and Access to Medications for Opioid Use Disorder.JAMA network open · 2022Article
- Don't "Waive" Goodbye to Education for Opioid Use Disorder.NAM perspectives · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAn Opioid Treatment Desert is an area with limited accessibility to medication-assisted treatment and recovery facilities for Opioid Use Disorder. We explored the concept of Opioid Treatment Deserts including racial differences in potential spatial accessibility and applied it to one Midwestern urban county using high resolution spatiotemporal data.
methodsWe obtained individual-level data from one Emergency Medical Services (EMS) agency (Columbus Fire Department) in Franklin County, Ohio. Opioid overdose events were based on EMS runs where naloxone was administered from 1/1/2013 to 12/31/2017. Potential spatial accessibility was measured as the time (in minutes) it would take an individual, who may decide to seek treatment after an opioid overdose, to travel from where they had the overdose event, which was a proxy measure of their residential location, to the nearest opioid use disorder (OUD) treatment provider that provided medically-assisted treatment (MAT). We estimated accessibility measures overall, by race and by four types of treatment providers (any type of MAT for OUD, Buprenorphine, Methadone, or Naltrexone). Areas were classified as an Opioid Treatment Desert if the estimate travel time to treatment provider (any type of MAT for OUD) was greater than a given threshold. We performed sensitivity analysis using a range of threshold values based on multiple modes of transportation (car and public transit) and using only EMS runs to home/residential location types.
resultsA total of 6,929 geocoded opioid overdose events based on data from EMS agencies were used in the final analysis. Most events occurred among 26-35 years old (34%), identified as White adults (56%) and male (62%). Median travel times and interquartile range (IQR) to closest treatment provider by car and public transit was 2 minutes (IQR: 3 minutes) and 17 minutes (IQR: 17 minutes), respectively. Several neighborhoods in the study area had limited accessibility to OUD treatment facilities and were classified as Opioid Treatment Deserts. Travel time by public transit for most treatment provider types and by car for Methadone-based treatment was significantly different between individuals who were identified as Black adults and White adults based on their race.
conclusionsDisparities in access to opioid treatment exist at the sub-county level in specific neighborhoods and across racial groups in Columbus, Ohio and can be quantified and visualized using local public safety data (e.g., EMS runs). Identification of Opioid Treatment Deserts can aid multiple stakeholders better plan and allocate resources for more equitable access to MAT for OUD and, therefore, reduce the burden of the opioid epidemic while making better use of real-time public safety data to address a public health epidemic that has turned into a public safety crisis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.